<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00260364</url>
  </required_header>
  <id_info>
    <org_study_id>CCR2631</org_study_id>
    <secondary_id>EudraCT No.: 2005-002715-24</secondary_id>
    <nct_id>NCT00260364</nct_id>
  </id_info>
  <brief_title>Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer</brief_title>
  <acronym>TARGET</acronym>
  <official_title>A Phase I-II Dose Finding and Early Efficacy Study of Combination Therapy With Erlotinib (Tarceva), Gemcitabine, Bevacizumab (Avastin), and Capecitabine in Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Professor Cunningham's Clinical Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic cancer is an aggressive, largely chemo-resistant disease with a poor prognosis.&#xD;
      EGFR and VEGF are both overexpressed in pancreatic cancers and thought to contribute to&#xD;
      tumour development and progression. The combination of gemcitabine and capecitabine has&#xD;
      recently been shown to be effective in advanced pancreatic cancer. The combination of&#xD;
      gemcitabine plus erlotinib has also been shown to be effective in advanced pancreatic cancer.&#xD;
      The aim of this study is to assess whether combining a chemotherapy doublet (gemcitabine plus&#xD;
      capecitabine) and a biologic doublet (erlotinib plus bevacizumab) is a safe and effective way&#xD;
      to treat advanced pancreatic cancer by targeting multiple tumour stimulating mechanisms&#xD;
      simultaneously.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To establish the safety and efficacy of a combination of four drugs (capecitabine,&#xD;
      gemcitabine, erlotinib and bevacizumab) in the treatment of patients with locally advanced or&#xD;
      metastatic pancreatic cancer. The study will be divided into two parts:&#xD;
&#xD;
      Part A (Phase I ): Is to establish the optimal dose of capecitabine for combination with&#xD;
      gemcitabine, bevacizumab and erlotinib. This part of the study is necessary in order to&#xD;
      characterise any increased side effects that may occur as a result of this combination of&#xD;
      drugs. The dose of capecitabine will be increased in cohorts containing 3 to 6&#xD;
      patients(according to standard dose escalation study design) whilst side effects are closely&#xD;
      monitored. The doses of the other three drugs will remain fixed during this period:&#xD;
&#xD;
        -  Gemcitabine: 1000 mg/m2 Days 1, 8, 15&#xD;
&#xD;
        -  Bevacizumab: 5 mg/kg every two weeks iv&#xD;
&#xD;
        -  Erlotinib: 100 mg/day orally&#xD;
&#xD;
      Maximum tolerated dose is the dose at which 2 out of a cohort of three to six patients&#xD;
      experience dose-limiting toxicity within the first cycle (28 days) of treatment. The&#xD;
      recommended dose for further evaluation will be one dose level below this.&#xD;
&#xD;
      Part B (Phase II): Once a recommended dose of capecitabine has been chosen, this will be used&#xD;
      for the remainder of the trial to further characterise the efficacy and safety of the drug&#xD;
      combination in this group of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A (Phase I): Dose-limiting Toxicity (DLT)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B (Phase II): Overall response rate (complete response and partial response)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary efficacy objectives of the trial are: One year survival and median overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival, Disease control rate.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The secondary safety objectives are: Toxicity,Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>and Assessment of pain</measure>
  </secondary_outcome>
  <enrollment type="Actual">44</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine orally days 1 -21</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib 100 mg orally days 1-28</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab 5 mg/kg intravenously every 2 weeks</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
          -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Not amenable to curative resection&#xD;
&#xD;
          -  No invasion of adjacent organs (e.g., duodenum or stomach) by CT scan&#xD;
&#xD;
          -  Unidimensionally measurable disease as assessed by CT in accordance with the Response&#xD;
             Evaluation Criteria in Solid Tumors (RECIST) guidelines.&#xD;
&#xD;
          -  No evidence of brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin ≤ upper limit of normal&#xD;
&#xD;
          -  Serum albumin &gt; 26 g/litre&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine ≤ 180 micromoles/litre OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No clinically significant cardiovascular disease&#xD;
&#xD;
          -  No uncontrolled hypertension (i.e., blood pressure &gt; 150/90 mm Hg on medication)&#xD;
&#xD;
          -  No arterial thromboembolic event within the past 6 months, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cerebrovascular accident&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
          -  No New York Heart Association grade II-IV congestive heart failure&#xD;
&#xD;
          -  No serious cardiac arrhythmia requiring medication&#xD;
&#xD;
        OTHER:&#xD;
&#xD;
          -  Not pregnant or breast feeding&#xD;
&#xD;
          -  Fertile patients must use effective contraception during study participation&#xD;
&#xD;
          -  No serious or non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No infection requiring parenteral antibiotics&#xD;
&#xD;
          -  No major bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No surgery within the last 28 days or anticipation for the need for major surgery&#xD;
             during the course of study treatment&#xD;
&#xD;
          -  No other active malignancy except non-melanoma skin cancer and cervical cancer in-situ&#xD;
&#xD;
          -  No history of known dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
          -  No lack of physical integrity of the upper gastro-intestinal tract, malabsorption&#xD;
             syndrome, or inability to take oral medication&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No previous chemotherapy, radiotherapy or other investigational drug treatment for&#xD;
             metastatic disease (including VEGF or EGFR antagonists)&#xD;
&#xD;
          -  No previous preoperative or adjuvant chemotherapy, radiotherapy or other&#xD;
             investigational drug treatment.&#xD;
&#xD;
          -  No full dose anti-coagulation (i.e. warfarin or full dose low molecular weight&#xD;
             heparin) prior to starting study treatment.&#xD;
&#xD;
          -  No ongoing treatment with aspirin (&gt;325 mg/day) or other medications known to&#xD;
             predispose to gastrointestinal ulceration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cunningham, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Marsden Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Royal Marsden Foundation Hospital NHS Trust</name>
      <address>
        <city>London and Surrey</city>
        <state>London</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>November 29, 2005</study_first_submitted>
  <study_first_submitted_qc>November 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2005</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent carcinoma of the pancreas</keyword>
  <keyword>Adenocarcinoma of the pancreas</keyword>
  <keyword>Stage II carcinoma of the pancreas</keyword>
  <keyword>Stage III carcinoma of the pancreas</keyword>
  <keyword>Stage IVA carcinoma of the pancreas</keyword>
  <keyword>Stage IVB carcinoma of the pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

